Skip to content

CorMedix CRMD Investments - Amortized Cost Basis

Investments - Amortized Cost Basis at other companies

Merck & Co. logo
Merck & Co.MRK
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's investments - amortized cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's investments - amortized cost basis?
CorMedix (CRMD) reported investments - amortized cost basis of $8.5M in Q4 2025.
How has CorMedix's investments - amortized cost basis changed year-over-year?
CorMedix's investments - amortized cost basis decreased by 75.1% year-over-year, from $34.16M to $8.5M.
What is the long-term trend for CorMedix's investments - amortized cost basis?
Over 3 years (2022 to 2025), CorMedix's investments - amortized cost basis has grown at a -28.2% compound annual growth rate (CAGR), from $22.96M to $8.5M.